Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer.
about
CIViC databasePharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyondPromising targets and current clinical trials in metastatic squamous cell lung cancerIntegrative modeling of multi-omics data to identify cancer drivers and infer patient-specific gene activityDetection of ALK protein expression in lung squamous cell carcinomas by immunohistochemistry.Synergistic Inhibitory Effects of Cetuximab and Cisplatin on Human Colon Cancer Cell Growth via Inhibition of the ERK-Dependent EGF Receptor Signaling Pathway.A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancerTumor-penetration and antitumor efficacy of cetuximab are enhanced by co-administered iRGD in a murine model of human NSCLC.Changes in the tumor microenvironment during lymphatic metastasis of lung squamous cell carcinoma.Reproducibility of the EGFR immunohistochemistry scores for tumor samples from patients with advanced non-small cell lung cancerPersonalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors.Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer.Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab.Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811.Meta-analysis of first-line therapies with maintenance regimens for advanced non-small-cell lung cancer (NSCLC) in molecularly and clinically selected populations.Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.Overcoming resistance to cetuximab with honokiol, a small-molecule polyphenol.The role of anti-EGFR agents in the first-line treatment of advanced esophago-gastric adenocarcinoma: a meta-analysis.Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients.Biomarker expression and druggable gene alterations for development of an appropriate therapeutic protocol for pulmonary adenosquamous carcinoma.Necitumumab in squamous non-small-cell lung cancer: how to move forward?Prognostic value of localization of epidermal growth factor receptor in lung adenocarcinoma.
P2860
Q27612411-F41821EB-83ED-4C38-8AF9-617E46F6DD5BQ28080730-ADC7C676-CA5F-4312-BBE5-EA60528A390EQ28083663-CDD01005-7A52-48F9-AD0E-B874FF70AEAFQ31044138-FB4435B6-F7E0-40A2-A765-9441322730D6Q35005185-D25E9E3C-2B4B-47FF-BE74-8D0A1A4BA02BQ36146089-E05F3204-3B11-4BA4-BCE4-113EF6A97CDDQ36656070-A4864B5A-56D1-4BAD-943C-7344D26883B3Q37406885-3FDB8908-9131-4C42-AB66-CEDD5F952F9EQ37611660-9DE9E0D2-0B2A-4BF5-9495-6E6E3F0BA5EAQ37701159-739139D4-6DD8-4681-881A-538E2EE15F59Q38400481-95AC715B-8F90-41A8-B497-E631B89C8618Q38757863-8955E163-219E-4200-B943-EBD58EE64C07Q38763641-0247156B-1CBF-4263-8AD3-C1BC3A9095A2Q38955008-9B0B9C43-9989-40CE-B28A-B18D565DD564Q38996898-BB3D2A02-E21F-4B08-BBF0-3B3427B5898BQ41311492-7D5782F3-8C77-4629-9FBB-00984DB7118DQ46261715-893B8F9A-3399-47DB-8979-0625FF9CE800Q46278768-3506EE06-B8EA-4131-9CFD-0F9A001DB614Q47120612-F6CA96EB-A2D7-4DB8-B3EC-1156D0277DB6Q47164059-8FE804AD-62AC-407E-B2EC-579E90F0C625Q49720695-84FD01E8-8C60-40DF-B758-C1C5F88D7746Q53016537-A1E91175-89C9-41A5-A6B8-364E36B7A511Q55020992-6402D609-1605-4C94-84B1-5780ECAEA1C6Q55460041-011BFB02-BD45-4EBE-BBB0-0081373D4BF6
P2860
Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Relationship between EGFR expr ...... ed non-small-cell lung cancer.
@ast
Relationship between EGFR expr ...... ed non-small-cell lung cancer.
@en
Relationship between EGFR expr ...... ed non-small-cell lung cancer.
@nl
type
label
Relationship between EGFR expr ...... ed non-small-cell lung cancer.
@ast
Relationship between EGFR expr ...... ed non-small-cell lung cancer.
@en
Relationship between EGFR expr ...... ed non-small-cell lung cancer.
@nl
prefLabel
Relationship between EGFR expr ...... ed non-small-cell lung cancer.
@ast
Relationship between EGFR expr ...... ed non-small-cell lung cancer.
@en
Relationship between EGFR expr ...... ed non-small-cell lung cancer.
@nl
P2093
P3181
P1476
Relationship between EGFR expr ...... ed non-small-cell lung cancer.
@en
P2093
Anja von Heydebreck
Frances A Shepherd
Hans Jürgen Grote
Ilhan Celik
Keith M Kerr
Kenneth J O'Byrne
Robert Pirker
Stephan Störkel
P304
P3181
P356
10.1097/JTO.0000000000000141
P577
2014-05-01T00:00:00Z